

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3929363

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS INC	06/15/2016
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10822303
CORRESPONDENCE DATA	
Fax Number:	(610)270-6812
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6102706812
Email:	us_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VN51946
NAME OF SUBMITTER:	CARLY MORROW
SIGNATURE:	/Carly Morrow/
DATE SIGNED:	06/22/2016
Total Attachments: 2	
source=VN51946 GEN Confirmatory Assignment#page1.tif	
source=VN51946 GEN Confirmatory Assignment#page2.tif	

CONFIRMATORY ASSIGNMENT

WE NOVARTIS VACCINES AND DIAGNOSTICS INC a company duly incorporated in the state of Delaware, and having a registered office at 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States of America do hereby declare that we are the sole owner of the following patents entitled "THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS"


Country	Application Date	Application Number	Grant Date	Patent Number
Australia	09-Apr-04	2004230485	05-Jul-09	2004230485
Australia	15-Apr-09	2009201478	29-Mar-12	2009201478
Belgium	09-Apr-04	04750188 7	10-Dec-14	EP1618127
Canada	09-Apr-04	2522379	23-Oct-12	2522379
European Patent Convention	09-Apr-04	04750188 7	10-Dec-14	EP1618127
France	09-Apr-04	04750188 7	10-Dec-14	EP1618127
United Kingdom	09-Apr-04	04750188 7	10-Dec-14	EP1618127
Germany	09-Apr-04	04750188 7	10-Dec-14	602004046301 9
Italy	09-Apr-04	502015000007128	10-Dec-14	EP1618127
Spain	09-Apr-04	04750188 7	10-Dec-14	EP1618127
United States	09-Apr-04	10/822303		

Whereas in accordance with the Patent Assignment Agreement dated 26 February 2015 between **NOVARTIS VACCINES AND DIAGNOSTICS INC** and **NOVARTIS AG**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS VACCINES AND DIAGNOSTICS INC** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **NOVARTIS AG** of Lichtstrasse 35, 4056 Basel, Switzerland


And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium

Dated this 15 day of June 2016

Signed for and on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC




Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC




Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC

Signed for and on behalf of
NOVARTIS AG




Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG



Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA



William R. Majarian
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA